Cortechs.ai and Philips partner to bring invaluable information to neurologists and radiologists fingertips.
(San Diego, CA) November 18, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce a partnership agreement with Royal Philips, a global technology company. The companies will collaborate to enhance physicians’ resources for assessing and quantifying neurodegeneration.
The outcome will provide automatic, accurate and consistent measurements of brain structures through 3D T1 MRI images, allowing neurologists and radiologists to easily review, assess, quantify and monitor brain volume loss and its changes over time, as compared to normative values.
“We’re excited to partner with Philips to provide advanced innovation to neurologists and radiologists worldwide,” said Guri Stark, Cortechs.ai’ CEO. “We believe this collaboration will significantly benefit clinicians in their assessment of neurodegeneration and provide a standard measurement solution for many brain disorders, including Alzheimer’s disease, epilepsy, multiple sclerosis, traumatic brain injury and more.”
About Cortechs.ai
Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
